flipper44,
The senior administrators at MHRA do not want to screw up an approval and have to backtrack like the FDA and aducanumab (for Alzheimer’s).
Your item #8 reminded me that this sort of treatment has zero side effects. For any approving body, that plus showing actual improvement for a victim equates to ‘No-Downside’. For MHRA, an extremely prompt approval could not be criticized.
We are past 12 weeks so an RFI would have been issued by now, if there was going to be one.
I appreciate Smith’s opinion that it could be 3Q, but I see approval next week.
Bullish